AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
- Sunday, August 7, 2022, 7:14
- PR Newswire
- Add a comment
First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE® Therapy in Small Cell Lung Cancer THOUSAND OAKS, Calif., Aug. 7, 2022…
About the Author
admin has written 21643 stories on this site.